297 related articles for article (PubMed ID: 23313564)
1. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.
Ball S; Marangell LB; Lipsius S; Russell JM
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():217-21. PubMed ID: 23313564
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
Wu WY; Wang G; Ball SG; Desaiah D; Ang QQ
Chin Med J (Engl); 2011 Oct; 124(20):3260-8. PubMed ID: 22088518
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
4. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment.
Pollack MH; Endicott J; Liebowitz M; Russell J; Detke M; Spann M; Ball S; Swindle R
J Psychiatr Res; 2008 Oct; 42(12):1042-9. PubMed ID: 18221755
[TBL] [Abstract][Full Text] [Related]
5. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
Allgulander C; Hartford J; Russell J; Ball S; Erickson J; Raskin J; Rynn M
Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
Russell JM; Weisberg R; Fava M; Hartford JT; Erickson JS; D'Souza DN
Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
[TBL] [Abstract][Full Text] [Related]
8. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A
Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
Davidson JR; Wittchen HU; Llorca PM; Erickson J; Detke M; Ball SG; Russell JM
Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
[TBL] [Abstract][Full Text] [Related]
11. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
[TBL] [Abstract][Full Text] [Related]
12. [Dynamic level observation of brain-derived neurotrophic factor in patients with first-episode generalized anxiety disorder].
Shen XH; Qian MC; Niu FR; Sun ST; Zhu YP; Yang JH; Lin M; Yu BR; Li L; Shen ZX
Zhonghua Yi Xue Za Zhi; 2011 Nov; 91(41):2939-41. PubMed ID: 22333619
[TBL] [Abstract][Full Text] [Related]
13. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
14. The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment remission in a Chinese Han population with generalized anxiety disorder.
Shen Z; Zhu J; Yuan Y; Ren L; Qian M; Lin M; Cai M; Zhang Z; Shen X
Psychiatry Res; 2019 Jan; 271():319-324. PubMed ID: 30529313
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
17. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
20. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
